Authors

Latest:

Merging Community Practices With an Academic Cancer Center

Consolidation of community oncology practices with hospital-based cancer centers is an accelerating trend that will affect future healthcare delivery models. This year, the Community Oncology Alliance reported hospital acquisitions and corporate mergers among 55% of 1338 community oncology practices surveyed, representing a 20% increase over the previous year's results.

Constantine Mantz, MD

Latest:

Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer

Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.

Constantine S. Tam, MD

Latest:

Long-Term Results of Patients Receiving Zanubrutinib in the Phase 3 ALPINE Study Confirm Sustained Benefit of Zanubrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Up to 6 Years of Follow-Up With the Long-Term Extension

Constantine S. Tam, MD discusses long-term results of patients receiving Zanubrutinib in the Phase 3 ALPINE study confirm sustained benefit of Zanubrutinib in patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Up to 6 years of follow-up with the long-term extension.

Constantine S. Tam, MD, MBBS

Latest:

SEQUOIA 5-year Follow-up in Arm C: Frontline Zanubrutinib Monotherapy in Patients with del(17p) and Treatment-naive CLL/SLL

Dr. Constantine S. Tam presents 5-year follow-up results from the SEQUOIA trial, showing that frontline zanubrutinib provides durable progression-free and overall survival with a consistent safety profile in patients with treatment-naïve CLL/SLL, including those with del(17p). Funding supported by BeOne Medicines USA, Inc. Content independently developed by OncLive.

Constantine Tam, MD

Latest:

Dr. Tam on Trials Investigating BGB-3111 in CLL and Waldenstrom's Macroglobulinemia

Constantine Tam, MD, discusses 2 trials investigating BTK inhibitor BGB-3111 in chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia.

Contagion&reg

Latest:

Top 5 Contagion® News Articles for the Week of August 27, 2017